Investors don't seem impressed with top-line data from two Phase 3 trials of Tesaro's (TSRO) NK-1 receptor antagonist rolapitant in chemotherapy-induced nausea and vomiting.
The studies met their primary endpoints of CR (no vomiting and no use of rescue medication) in the delayed phase.
However, neither trial hit statistical significance in the acute and overall phases (secondary endpoints).
The company says preparations are ongoing for an NDA submission in mid-2014. (PR)
TSRO -14% premarket.